Published: November 22, 2017

Introduction {#sec1}
============

Mature muscle cells in the mammalian heart proliferate very slowly limiting its regenerative capacity after injury. Accordingly, cardiomyocytes dying after infarction are not replaced by new ones but instead characteristic fibrotic scar tissue forms, which interferes with potential cardiomyocyte regeneration, impairs heart function, and may later result in heart failure ([@bib16]). Therefore, to regenerate the injured heart, exogenous or endogenous cardiomyocytes are needed to replace those lost.

Multiple cell-based strategies to regenerate damaged post-mitotic tissues have been described (reviewed by [@bib22]). Human pluripotent stem cells (hPSCs) are also considered a potential source of cardiomyocytes for transplantation strategies and are already an excellent *in vitro* model to study the complex transcriptional networks and molecular interactions that regulate cardiomyogenesis ([@bib1], [@bib2]). Recently, epicardial-derived cells have also emerged as a source of various cardiovascular cell types, including endothelial cells, smooth muscle cells, and fibroblasts ([@bib4]). However, *in vivo* cardiomyocyte formation from epicardial cells remains controversial ([@bib7]).

During embryogenesis, proepicardial (epicardial progenitor) cells form the epicardium (the monolayer of epithelium that covers the heart surface), part of the coronary vasculature, and a heterogeneous population of non-muscular cardiac interstitial cells (CICs) ([@bib23], [@bib24]). Among epicardial-derived CICs, a platelet-derived growth factor receptor α-positive (Pdgfrα^+^) cell subpopulation has been identified in mice, which displays cardiac stem cell properties and is able to expand clonally and differentiate into endothelial and smooth muscle cells, fibroblasts, and cardiomyocytes ([@bib6]). A recent study indicated that CICs include a population of cardiac fibroblast progenitors, which massively expand after ischemic damage ([@bib24]). Therefore, modulation of epicardial cell differentiation into different cardiac cell types might be highly relevant in developing cell-based strategies for heart repair.

Several studies have identified some of the relevant cues that regulate cardiomyocyte differentiation and diversification. Among these, retinoic acid (RA) ([@bib9], [@bib21]) and bone morphogenetic protein 4 (BMP4) ([@bib25]) have been shown to be important in specification of cardiac inflow cardiomyocyte differentiation. Other signals, most especially WNTs, have also been involved in the regulation of cardiomyocyte differentiation ([@bib18]), but their role during early cardiogenesis remains elusive, probably due to cardiomyocyte progenitor sensitivity to WNT dose and the complexity of WNT signaling redundancy ([@bib12]). Nevertheless, two recent reports have successfully linked *in vivo* information on development to an *in vitro* hPSC model and demonstrated epicardial-like cell differentiation from human embryonic stem cells (hESCs) by modulating WNT and BMP signaling ([@bib15], [@bib27]). Here, we have extended and complemented these studies by identifying developmentally relevant transitional stages between lateral plate mesoderm and the embryonic epicardium *in vitro*. In particular, we have focused on the proepicardial stage, at which cardiac inflow cardiomyocytes and fibroblasts segregate from a common progenitor in response to integrated BMP4 and fibroblast growth factor 2 signals, resulting in the loss of cardiomyocyte differentiation potential in primitive epicardial cells ([@bib25]).

To study mesodermal specification into the epicardial lineage while monitoring cardiomyogenic potential, we used a transgenic *NKX2-5*^EGFP/w^ hESC line in which *GFP* transcription is under control of the endogenous myocardiogenic transcription factor *NKX2-5* ([@bib10]), with RA, BMP4, and RA + BMP4 at previously tested concentrations ([@bib9]; reviewed in [@bib2]). We found that epicardial cell-like differentiation in the presence of RA + BMP4 was at the expense of cardiomyocyte formation, as demonstrated by the failure to express *GFP*, which was also confirmed in human induced pluripotent stem cells (hiPSCs). Since WNT signaling disruption after *β-catenin* ablation in the proepicardium/epicardium does not affect proepicardial or epicardial formation, but rather affects epicardial differentiation into coronary blood vessel cells ([@bib30]), and WNTs appeared dispensable for epicardial differentiation of hESCs in an earlier study ([@bib15]), we did not include WNT in our protocols.

Our findings indicated that BMP4 and RA synergistically induce hPSC differentiation into proepicardial/epicardial cells by blocking cardiomyocyte differentiation and promoting proepicardium-specific gene expression. The hPSC-derived epicardial progenitor cells showed similar adhesion and migration properties as embryonic proepicardium, most strikingly when grafted into the prospective pericardial cavity of chick embryos. This demonstrated their functional integrity as a model for further understanding of the epicardium in the human heart.

Results and Discussion {#sec2}
======================

RA + BMP4 Synergistically Promote *NKX2-5*^EGFP/w^ hESCs Differentiation into Proepicardial-like Cells in the Absence of Exogenous WNTs {#sec2.1}
---------------------------------------------------------------------------------------------------------------------------------------

Previously, various cytokines and small molecules have been used sequentially to initiate cardiac differentiation of *NKX2-5*^EGFP/w^ hESCs cultured as aggregates/embryoid bodies (EBs) ([@bib10]). Under these conditions, *NKX2-5*^EGFP/w^ hESCs robustly differentiate into cardiomyocytes after 9--10 days in culture ([Figure 1](#fig1){ref-type="fig"}A). To test whether *NKX2-5*^EGFP/w^ hESCs differentiate into proepicardial-like cells, we modified this protocol by adding BMP4 and RA at different time points ([Figure 1](#fig1){ref-type="fig"}B).Figure 1RA + BMP4 Synergistically Promote Proepicardial Cell Differentiation from *NKX2-5*^EGFP/w^ hESCs(A) *NKX2-5*^EGFP/w^ hESCs differentiate into GFP^+^-bearing embryoid bodies (EBs) after protocol 1 (B).(B) Culture supplements are indicated as related to specific protocols.(C) Average percentages (n = 7 independent experiments) of GFP^−^ and PDGFRα^+^ FACS analyzed cells (culture day 9). Data represent mean ± SD (ns, non-significant; ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001).(D) Representative FACS plots depicting GFP^+^ and PDGFRα^+^ cell percentages after protocols 1--4 (culture day 9).(E) qRT-PCR validation of cardiac versus proepicardial-like gene expression in hESCs after protocols 1--4 (culture day 9, n = 4 independent experiments). Data are presented as mean ± SD (ns, non-significant; ^∗^p \< 0.05; ^∗∗^p \< 0.01).(F) qRT-PCR validation of cardiac versus proepicardial-like gene expression in hPSCs after monolayer differentiation (culture day 9, n = 3 independent experiments). Data represent mean ± SEM (all differences between groups are non-significant, p \< 0.05). Scale bars, 100 μm in (A).

Morphologically, BMP4- and/or RA-treated EBs (protocols 2--4) were similar to control EBs (protocol 1) (data not shown). However, adding BMP4 and/or RA on days 3 and 4 (protocols 2--4) increased the appearance of cells expressing the mesodermal/epicardial marker PDGFRα ([@bib13], [@bib14]) in GFP^−^*NKX2-5*^EGFP/w^ hESCs, as assessed by fluorescence-activated cell sorting (FACS) analysis at day 9 ([Figure 1](#fig1){ref-type="fig"}C); this effect was greatest after protocol 4 (RA + BMP4) ([Figures 1](#fig1){ref-type="fig"}C--1E). Quantification of GFP^+^ cells in each of the four treatments (day 9) confirmed a significant decrease (but not abrogation) of *NKX2-5*^EGFP/w^ hESC differentiation into GFP^+^ cardiomyocytes after protocol 4 (RA + BMP4; [Figures 1](#fig1){ref-type="fig"}C and 1D). Gene expression analysis of cells emerging from protocols 2 and 3 ([Figure 1](#fig1){ref-type="fig"}B) indicated that RA alone induced a small increase in epicardial/proepicardial-associated genes such as *WT1*, *TCF21*, and *TBX18*, while robustly suppressing cardiomyocyte-associated genes such as *NKX2-5* and *α-ACTININ* ([Figure 1](#fig1){ref-type="fig"}E). Thus, RA is not only able to activate epicardial/proepicardial genes, but is also sufficient to suppress *NKX2-5* and cardiac *α-ACTININ* expression. In accordance with these results, RA signaling in zebrafish anterior lateral plate mesoderm has also been shown to restrict the size of the cardiac progenitor pool ([@bib17]). These findings suggested that RA-dependent cardiac differentiation from hESC *in vitro* recapitulated development *in vivo* ([@bib21]). Interestingly, BMP4, as compared with RA, increased epicardial/proepicardial gene expression (*WT1*, *TCF21*, and *TBX18*), but did not reduce the expression of cardiomyocyte genes *NKX2-5* and *α-ACTININ* ([Figure 1](#fig1){ref-type="fig"}E). The combination of BMP4 and RA further increased the expression of epicardial/proepicardial genes, such as *WT1*, *TCF21*, and *TBX18*, while efficiently reducing the expression of *NKX2-5* and *α-ACTININ* ([Figure 1](#fig1){ref-type="fig"}E) in 9 days only (for comparison, the previously reported WNT3 + BMP4 combination promoted epicardial differentiation in 15 days, [@bib27]). These results indicated that BMP4 and RA synergistically activate an "epicardial lineage-like" gene program at the expense of cardiomyocyte differentiation, but without fully abrogating cardiomyocyte ([Figure 1](#fig1){ref-type="fig"}D) or endothelial cell differentiation in culture (data not shown). In our protocol, EBs were supplemented with BMP4 from day 3, and with RA + BMP4 from days 4 to 9, i.e., during the temporal window marked by the transient expression of the cardiac mesoderm specification marker *MESP1* (day 4) and the initiation of cardiovascular lineage commitment as marked by the expression of *NKX2-5*, *GATA4*, and *MEF2C* genes (day 9) ([@bib8]).

RA + BMP4 Synergistically Promote Differentiation of hPSCs into Proepicardial-like Cells in Monolayer Culture {#sec2.2}
-------------------------------------------------------------------------------------------------------------

In addition to 3D hPSC differentiation in EBs, we also examined the effect of RA + BMP4 on the induction of proepicardial-like cells from hPSCs in 2D monolayer culture by adapting a protocol we recently described for simultaneous differentiation of cardiomyocytes and endothelial cells from common cardiac mesoderm ([@bib11]) ([Figure S1](#mmc1){ref-type="supplementary-material"}A and S1A′). In agreement with our previous results in EBs, the presence of RA + BMP4 from day 3 was again critical for the induction of GFP^−^/PDGFRα^+^ epicardial/proepicardial cells and for the upregulation of *WT1* expression in 2D differentiations ([Figures S1](#mmc1){ref-type="supplementary-material"}B and S1C). Gene expression profiling revealed comparable expression levels of epicardial/proepicardial genes (*WT1*, *TCF21*, *TBX18*, and *COUP-TFII*) at day 9 of differentiation in all the different hPSC lines (the *NKX2-5*^EGFP/w^ hESCs and the wild-type hiPSC lines NCRM1 and SFLB6, see [@bib31]) used in this study ([Figure 1](#fig1){ref-type="fig"}F), indicating the robustness of the protocol. Notably, inhibition of WNT signaling by XAV supplementation at day 3 had little or no effect on the differentiation of epicardial/proepicardial cells in 2D monolayer differentiation conditions ([Figures S1](#mmc1){ref-type="supplementary-material"}A′--S1C). We also tested the effect of inhibition of WNT signaling using cultured embryonic day 9.5 (E9.5) mouse proepicardia *in vitro.* Importantly, WNT antagonist IWP2 also did not affect expression of the proepicardial genes *WT1* and *COUP-TFII* in these experiments ([Figure S2](#mmc1){ref-type="supplementary-material"}).

CD31, GFP, and PDGFRα Expression Profiles Define Three Cell Phenotypes after *NKX2-5*^EGFP/w^ hESC Treatment with RA + BMP4 {#sec2.3}
---------------------------------------------------------------------------------------------------------------------------

Since cardiomyocyte differentiation from *NKX*2-5^EGFP/w^ hESCs can be monitored through GFP expression, we refined the characterization of cell phenotypes after culture protocol 4 in EBs ([Figure 1](#fig1){ref-type="fig"}B) using GFP as a landmark for cardiac versus non-cardiac cell differentiation. Cells were sorted by FACS based on their GFP and CD31 expression, and only the CD31^−^ fractions (non-endothelial cells) were selected for further characterization. As expected, cardiogenic (*NKX2-5/TBX5*) gene expression in CD31^−^/GFP^−^ cells was almost undetectable when compared with CD31^--^/GFP^+^ cells ([Figure S3](#mmc1){ref-type="supplementary-material"}A). However, the expression of *WT1*, *TCF21*, *TBX18*, and *COUP-TFII* genes was significantly increased in the CD31^−^/GFP^−^ cell fraction compared with the CD31^−^/GFP^+^ population ([Figure 2](#fig2){ref-type="fig"}A), as was the expression of other epicardial/proepicardial genes, such as *RALDH2*, *E-CADHERIN*, and *α4 INTEGRIN* ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Expression of *COUP-TFII*, an orphan nuclear receptor critical for mesodermal differentiation into multiple cell types ([@bib28]), was of special interest since it is strongly expressed by proepicardial cells but only at relatively low levels by epicardial cells *in vivo* ([@bib19]). This suggests that *COUP-TFII* expression identifies a more primitive set of cells in the septum transversum-proepicardium-epicardium continuum ([@bib5]), and we thus refer to these cells as proepicardial/epicardial-like cells.Figure 2Proepicardial Gene Expression in RA + BMP4-Treated *NKX2-5*^EGFP/w^ hESC-Derived Cells(A) qRT-PCR of selected gene transcripts (culture day 9) confirms increase in cardiomyocyte and decrease in proepicardial markers in CD31^−^/GFP^+^ with respect to CD31^−^/GFP^−^ cells (n = 4 independent experiments). Data are presented as mean ± SD (^∗^p \< 0.05 by unpaired t test).(B--E) *WT1* and *COUP-TFII* mRNA expression in RA + BMP4-treated *NKX2-5*^EGFP/w^ hESCs (CD31^−^/GFP^−^) is paralleled by WT1 (B and C) (red) and COUP-TFII (D and E) (red) protein expression *in vitro*.(F) qRT-PCR analysis of proepicardial markers (*WT1*, *TCF21*, *TBX18*, and *COUP-TFII*) in CD31^−^/GFP^−^/PDGFRα^+^ versus CD31^−^/GFP^−^/PDGFRα^−^ cells (n = 5 independent experiments). Data are presented as mean ± SD (^∗^p \< 0.05 by unpaired t test).(G--N) CD31^−^/GFP^−^/PDGFRα^+^ are epithelial, PAN-CADHERIN^+^ cells. CD31^−^/GFP^−^/PDGFRα^+^ and CD31^−^/GFP^+^/PDGFRα^±^ cell co-culture (n = 12) results in the formation of cells aggregates showing a segregation between GFP^+^ and GFP^−^ cells (white dashed lines separate these two cell types); CD31^−^/GFP^−^/PDGFRα^+^ cells grow over GFP^+^ cells (H), forming a CK^+^ epithelium (I and J) (arrowheads) and expressing epicardial markers such as WT1 (K and L) (arrowheads) and α-SMA (M) (arrowheads). All the cells remain CD31^−^ (N). Scale bars, 50 μm in (B)--(E), (G), and (J); 100 μm in (H), (I), (K), and (M); 10 μm in (L); and 25 μm in (N).

Immunocytochemistry confirmed WT1 and COUP-TFII nuclear protein accumulation in CD31^−^/GFP^−^ cells, but not in CD31^−^/GFP^+^ ([Figures 2](#fig2){ref-type="fig"}B--2E), suggesting that the identity of hESC-derived CD31^−^/GFP^−^ cells was more similar to epicardial progenitors (proepicardial cells) than to epicardial cells. To precisely define the nature of CD31^−^/GFP^−^ cells, we sorted the cells on the basis of the PDGFRα mesodermal/epicardial marker ([@bib13], [@bib14]). Our results confirmed that the expression of the proepicardial-related genes *WT1*, *TCF21*, *TBX18*, and *COUP-TFII* ([Figure 2](#fig2){ref-type="fig"}F) was higher in CD31^−^/GFP^−^/PDGFRα^+^ than in CD31^−^/GFP^−^/PDGFRα^−^ cells. 2D monolayer differentiation resulted in robust induction of proepicardial-like cells from hPSCs without prior need for enrichment of the PDGFRα^+^ population ([Figure S3](#mmc1){ref-type="supplementary-material"}B). These cells also expressed typical proepicardial-associated genes *WT1*, *TCF21*, *TBX18*, and *COUP-TFII* ([Figure S3](#mmc1){ref-type="supplementary-material"}C).

Immunocytochemical analysis of PAN-CADHERIN expression confirmed that these cells were epithelial in phenotype ([Figure 2](#fig2){ref-type="fig"}G), as expected for epicardial cells, which are a subtype of visceral mesothelium. Furthermore, proepicardial-like cells expanded from the monolayer differentiation protocol exhibited typical cobblestone-like morphology with nuclear localization of WT1 and COUP-TFII ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B). We have shown that RA + BMP4-treated *NKX2-5*^EGFP/w^ hESCs mostly differentiate into PDGFRα^+^/GFP^−^ non-cardiomyocyte cells, which express proepicardial genes such as *WT1*, *TCF21*, *TBX18*, and *COUP-TFII*. However, some RA + BMP4-treated *NKX2-5*^EGFP/w^ hESCs still differentiated into PDGFRα^+^/GFP^+^ cardiomyocytes. Further research is required to ascertain whether those cardiomyocytes could secondarily derive from PDGFRα^+^/GFP^−^/TBX18^+^/WT1^+^/COUP-TFII^+^ proepicardial-like cells.

CD31^−^/GFP^−^/PDGFRα^+^ Cells Display Embryonic Proepicardial-like Behavior *In Vitro* and *In Ovo* {#sec2.4}
----------------------------------------------------------------------------------------------------

To test the functional properties of (pro)epicardial-like CD31^−^/GFP^−^/PDGFRα^+^ cells *in vitro*, *NKX2-5*^EGFP/w^ hESCs were cultured following protocol 4 (see [Figure 1](#fig1){ref-type="fig"}B). CD31^−^/GFP^−^/PDGFRα^+^ (proepicardial), and CD31^−^/GFP^+^/PDGFRα^±^ (myocardial) cell populations were sorted at day 9 of differentiation (D9, see [Figure 1](#fig1){ref-type="fig"}B), and then mixed (1:1) to form aggregates *in vitro*. At day 13 of differentiation, two different cell phases were evident in the aggregates, only one of them expressing GFP ([Figure 2](#fig2){ref-type="fig"}H). Immunohistochemical analysis of the aggregates ([Figures 2](#fig2){ref-type="fig"}I and 2J) identified cytokeratin (CK) (an epithelial intermediate filament) in the CD31^−^/GFP^−^/PDGFRα^+^ cell population, which also expressed WT1 ([Figures 2](#fig2){ref-type="fig"}K and 2L), and smooth muscle-specific α-actin (α-SMA) ([Figure 2](#fig2){ref-type="fig"}M), but remained CD31^−^ ([Figure 2](#fig2){ref-type="fig"}N). The characteristic distribution of some CD31^−^/GFP^−^/PDGFRα^+^/CK^+^ cells over the surface of the structure suggested that this cell population had grown and spread over the CD31^−^/GFP^+^/PDGFRα^±^ cells ([Figure 2](#fig2){ref-type="fig"}J), recapitulating normal proepicardial cell growth over the embryonic myocardium to form the primitive epicardium. Previous studies indicated that epicardial α4β1 integrin (or VLA-4) plays a pivotal role in migration and adhesion to the heart ([@bib29]). Therefore, we utilized a small-molecule α4β1 antagonist (BIO5192) to confirm the importance of this interaction for the formation of *in vitro* aggregates. BIO5192-treated aggregates displayed a marked disruption of proepicardial-like CD31^−^/GFP^−^/PDGFRα^+^ cell aggregation with the cells dispersing in the culture, while myocardial CD31^−^/GFP^+^/PDGFRα^±^ cells remained as a coherent cell mass in control and BIO5192-treated aggregates ([Figure S4](#mmc1){ref-type="supplementary-material"}C).

Functional properties of CD31^−^/GFP^−^/PDGFRα^+^ cells were also tested *in ovo*. RA + BMP4-treated *NKX2-5*^EGFP/w^ hESC EBs (6 days of culture, protocol 4) were grafted into chick embryo hosts (HH17) ([Figure 3](#fig3){ref-type="fig"}A). After 7 days, these EBs were identified by their expression of a human pan-nuclear (hNu) marker ([Figures 3](#fig3){ref-type="fig"}B--3D). Some of the donor EBs were attached to, and partially spread over, the myocardial surface ([Figures 3](#fig3){ref-type="fig"}C and 3D). Groups of grafted cells migrated into the myocardial layers ([Figure 3](#fig3){ref-type="fig"}D). The outer surface of the EBs was covered by CK-expressing epithelial cells ([Figure 3](#fig3){ref-type="fig"}E). All cells in the EBs expressed the hNu antigen ([Figure 3](#fig3){ref-type="fig"}F), while only some expressed the proepicardial markers COUP-TFII ([Figure 3](#fig3){ref-type="fig"}G) and WT1 ([Figure S4](#mmc1){ref-type="supplementary-material"}D). No GFP^+^ cells were detected in the host myocardium at any time ([Figure S4](#mmc1){ref-type="supplementary-material"}D). COUP-TFII^+^ cells were located in the inner layers of the EBs ([Figure 3](#fig3){ref-type="fig"}H) or in their epithelial surface ([Figure 3](#fig3){ref-type="fig"}I); in both cases the cells expressed the epithelial marker CK ([Figures 3](#fig3){ref-type="fig"}H and 3I). Groups of hNu^+^ cells on the surface and inside the EBs expressed the α-SMA marker ([Figures 3](#fig3){ref-type="fig"}J--3M); some of these α-SMA^+^ cells were able to invade the myocardium ([Figures 3](#fig3){ref-type="fig"}L and 3M). In addition, we examined the *in ovo* functional properties of proepicardial-like cells derived from the optimized 2D monolayer differentiation protocol (RA + BMP4) ([Figure S1](#mmc1){ref-type="supplementary-material"}A). For this, expanded hiPSC-derived proepicardial-like cells were counterstained with the CMTPX CellTracker Red and subsequently injected as cell suspensions into the prospective pericardial cavity of Hamburger-Hamilton stage 16--17 chick embryos ([Figure 3](#fig3){ref-type="fig"}N). Both the hESC-derived ([Figures 3](#fig3){ref-type="fig"}O--3Q) and hiPSC-derived proepicardial-like cells ([Figures 3](#fig3){ref-type="fig"}R--3U) attached and spread over the myocardial surface. Some of these cells expressed the WT1 protein ([Figures 3](#fig3){ref-type="fig"}Q and 3U) and were found to invade the myocardial layers ([Figures 3](#fig3){ref-type="fig"}Q, 3T, and 3U). These results differ from those published previously ([@bib15]), which reported the presence of intravascularly injected hESC-derived cells in the subepicardial space and the walls of coronary arteries, but not in the epicardial epithelium itself. Our finding that hPSC-derived CD31^−^/GFP^−^/PDGFRα^+^ cells can form an epicardial-like epithelial envelope over the chick host myocardium confirms that these cells possess critical morphogenetic properties of epicardial progenitor cells, although the extent of hPSC-derived proepicardial-like cell migration over the chick myocardium is likely to be limited by intrinsic differences between the host and the donor.Figure 3Functional Properties of CD31^−^/GFP^−^/PDGFRα^+^ Cells*NKX2-5*^EGFP/w^ hESC-derived EBs (arrow) treated under protocol 4 were grafted into chick embryos as shown in (A) (n = 10 independent experiments). Some EBs attach to the myocardium of HH17 chick host hearts (B) (arrow), the graft is magnified in (B′); donor cells spread over the myocardium (C and D) (arrows) or migrate into the myocardium (C) (arrowheads). Cells in the EB surface express the epithelial marker CK (E) (green). COUP-TFII expression in EB cells is conspicuous (F and G) (arrowheads in G); some COUP-TFII^+^ cells express cytokeratin both inside (H) (arrows) and on the surface of EBs (H and I) (arrowheads). Many cells at the EB surface express α-SMA, arrowheads in (J) and (K); the area marked by the asterisk in (J) is magnified in (K); some α-SMA^+^ cells invade the myocardium; arrowheads in (L) and (M) and the dashed line in (L) mark the border between the EB and the host myocardium. hPSC-derived proepicardial/epicardial-like cells were stained with CellTracker Red and injected into the pericardial cavity of chick embryo hearts as shown (N) (NKX2-5^EGFP/w^, n = 10 independent experiments; SFLB6, n = 10 independent experiments). Some proepicardial/epicardial-like cells (red staining) attached to the myocardium (cTnT, green tissue) of HH17 chick host (arrows in O, R, and S); some donor cells spread over the myocardium (P, Q, T, and U) (arrows) and some other cells migrated into the myocardium (Q, T, and U) (arrowheads). CellTracker Red^+^ cells expressed a human nuclear-specific marker (hNuclei) (P and T) (white). WT1 expression is also conspicuous in human donor cells (Q) (white) and (U) (green). EB, embryoid body; H, heart; Myo, myocardium. Scale bars, 500 μm in (B); 25 μm in (C), (D), (E), (H), (K), and (L); 50 μm in (F), (G), (O), (Q), (S), (T), and (U); 10 μm in (I); 100 μm in (J) and (P); 15 μm in (M); and 200 μm in (R).

In this work we have shown that RA + BMP4-treated hPSCs can differentiate into mesodermal cells displaying a gene expression profile and functional properties of proepicardial cells, a subpopulation of the lateral plate mesoderm that accumulates at the venous (posterior) pole of the embryonic heart and is essential during heart embryogenesis ([@bib23]). Proepicardial cells have been hypothesized to be multipotent ([@bib26]), as they can differentiate into epicardial epithelial cells, endothelium, smooth muscle cells, fibroblasts, and cardiomyocytes ([@bib4]) under different *in vivo* and/or *in vitro* conditions. Interestingly, the combined, persistent expression of *PDGFRα* and *COUP-TFII* in a proportion of hPSC-derived CD31^−^/GFP^−^ cells suggests they still retain multipotency associated with subpopulations of the primitive lateral mesoderm including the proepicardium ([@bib6], [@bib19]), as summarized in [Figure 4](#fig4){ref-type="fig"}.Figure 4The Proepicardium and the Lateral Plate MesodermBlastodermal derivatives in E8.5 (A--C) and E9.5--E10.0 (C--G) mouse embryos. WT1 (F) (green) is expressed in the majority of splanchnic lateral mesodermal cells, including the proepicardium (PRO), the primitive epicardium (EP), and the pericardium (PE). On the contrary, COUP-TFII expression (F) (red) is strong in cardiac inflow myocardial progenitors (asterisks), proepicardial cells (PRO), but not epicardial (EP) or pericardial (PE) cells. Scale bars, 200 μm in (F) and 10 μm in (G)--(G″).

We conclude that our cell culture protocol is a rapid and robust method for generating proepicardial (epicardial progenitor)-like cells in both aggregates and monolayer cultures with intrinsic cardiomyogenic potential that can be further manipulated. This cell platform could be relevant for the study of cell and molecular pathophysiological mechanisms underlying different cardiovascular diseases, and could also facilitate stem cell-based therapies to regenerate and repair injured cardiac tissues.

Experimental Procedures {#sec3}
=======================

hESC Culture and Differentiation to Cardiomyocytes and Epicardial-like Cells {#sec3.1}
----------------------------------------------------------------------------

Undifferentiated *NKX2-5*^EGFP/w^ hESCs were cultured as described in the [Supplemental Information](#mmc1){ref-type="supplementary-material"}. BMP4 and RA concentrations used have been previously tested in other studies on hESC differentiation into mesodermal cells and cardiogenic progenitors ([@bib3], [@bib9]).

Monolayer Differentiation of hPSCs to Epicardial-like Cells {#sec3.2}
-----------------------------------------------------------

Cardiac mesoderm was induced in monolayer culture as described previously ([@bib11]). The following hPSC lines were used: *NKX2-5*^EGFP/w^ hESCs and two control hiPSC lines SFLB6 ([@bib31]) and NCRM1 (NIH Center for Regenerative Medicine \[NIH CRM\]), obtained from RUDCR Infinite Biologics at Rutgers University. For hPSC-derived cardiomyocyte differentiation BPEL medium (BSA polyvinyl alcohol essential lipids \[[@bib20]\]) supplemented with a mixture of cytokines was used (see [Supplemental Information](#mmc1){ref-type="supplementary-material"}).

Flow Cytometry (FACS) and Cell Sorting {#sec3.3}
--------------------------------------

On day 9 of differentiation, EBs or monolayers were dissociated using TrypLE Select 1× (Gibco), washed once with FACS buffer containing 10% fetal bovine serum, and washed again in FACS buffer (Ca^2+^- and Mg^2+^-free PBS plus 0.5% BSA, 2 mM EDTA). Cells were analyzed with the MACSQuant VYB cytometer (Miltenyi) and sorted on FACSAria III flow cell sorter (BD Biosciences) using antibodies as listed in the [Supplemental Information](#mmc1){ref-type="supplementary-material"}.

Gene Expression Analysis {#sec3.4}
------------------------

Extraction of RNA from EB samples (protocols 1--4, day 9 of culture) was performed using the RNeasy-Micro Kit (QIAGEN), whereas the NucleoSpin RNA XS Kit (MACHEREY-NAGEL) was used in sorted cell populations and monolayer cultures. RNA was submitted to reverse transcription to obtain cDNA (1 μg) using the Iscript cDNA Kit (Bio-Rad). For details on the full procedure and primers used see the [Supplemental Information](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc1){ref-type="supplementary-material"}.

Immunocytochemistry {#sec3.5}
-------------------

Cell pools were sorted according to their cell surface expression profile (CD31; GFP; PDGFRα) and grown in regular BPEL medium. After 6 days of culture, cells were fixed in 4% paraformaldehyde and processed for immunohistochemistry as described in the [Supplemental Information](#mmc1){ref-type="supplementary-material"}.

EB *In Ovo* Transplantations {#sec3.6}
----------------------------

*NKX2-5*^EGFP/w^ hESC-derived EBs were generated using protocol 4 (RA + BMP4; [Figure 1](#fig1){ref-type="fig"}A), cultured for 7 days, and grafted into the prospective pericardial cavity of HH16-17 chick embryos. Twelve transplantations were performed; only ten grafts (those attached to the myocardium) were analyzed.

hPSC *In Ovo* Transplantation {#sec3.7}
-----------------------------

*NKX2-5*^EGFP/w^ hESCs and SFLB6 hiPSCs were differentiated and cultured using a monolayer differentiation protocol ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Differentiated cells were sorted and PDGFRα^±^ cells were expanded, stained with CellTracker Red, and then injected into the prospective pericardial cavity of HH16-17 chick embryos. Donor hearts were directly examined under a fluorescence dissecting scope and further characterized by immunohistochemistry. The full protocol is available in the [Supplemental Information](#mmc1){ref-type="supplementary-material"}.

Culture of Cell Aggregates {#sec3.8}
--------------------------

*NKX2-5*^EGFP/w^ hESCs from protocol 4 (RA + BMP4; [Figure 1](#fig1){ref-type="fig"}A) were used to form cell spheroids. Cells were selected and cultured as described in the [Supplemental Information](#mmc1){ref-type="supplementary-material"}.

Statistical Analysis {#sec3.9}
--------------------

Statistical significance was assessed by Student\'s t test (comparison of two groups) or one-way ANOVA with Tukey\'s multiple comparison test (comparison of four groups). Significance by Student\'s t test was attributed to comparisons with values of p \< 0.05. All error bars represent SD.
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